Abstract: Objective To explore the effects of capreomycin combined with moxifloxacin on serum T cell subsets and procalcitonin(PCT)levels in pulmonary tuberculosis patients with multi-drug resistance. Methods A total of 82 pulmonary tuberculosis patients with multi-drug resistance were randomly divided into two groups, with 41 cases in each group. The control group was treated with levofloxacin and capreomycin, and the experimental group was treated with moxifloxacin and capreomycin. The clearance rate of sputum bacteria, adverse reactions, changes of serum T cell subsets(CD4⁺CD25⁺/CD4⁺, CD4⁺CD25⁺CD127^low/CD4⁺), inflammatory factor indexes ［PCT, tumor necrosis factor-α(TNF-α), interleukin-17(IL-17), interleukin-1(IL-1)］, and liver function indexes［total protein(TP), alkaline phosphatase(AKP), alanine aminotransferase(ALT)］were compared between the two groups. Results The clearance rate of sputum bacteria in the experimental group was 90.24%, which was significantly higher than 70.73% in the control group(P<0.05). There were no significant differences in the incidence of adverse reactions such as tachycardia, leukopenia and liver function damage(P>0.05). After treatment, the levels of CD4⁺CD25⁺CD127^low/CD4⁺, CD4⁺CD25⁺/CD4⁺ in both groups decreased significantly, and were significantly lower in the experimental - group than those in the control group(P<0.05). After treatment, the levels of IL-17, TNF-α, IL-1 and PCT in both groups were significantly improved, and the levels of TNF-α, IL-1 and PCT in the experimental group were significantly lower than those in the control group, while the level of IL-17 in the experimental group was significantly higher than that in the control group(P<0.05). After treatment, ALT and AKP levels in both groups were significantly higher than those before treatment, while TP level was significantly lower than that before treatment, but there were no significant differences in these indexes between the two groups(P>0.05). Conclusion Moxifloxacin combined with capreomycin is effective and safe in treatment of pulmonary tuberculosis patients with multi-drug resistance, which can increase the clearance rate of sputum bacteria, regulate the levels of serum T cell subsets, and reduce the serum PCT level.